The origins of cancer immunotherapy trace back to the pioneering work of Dr. William Coley, who observed tumor clearance in some patients that received injections of bacteria 12 -a result now attributed to leukocyte activation [13] [14] [15] . Since then, a multitude of studies have demonstrated that bacteria preferentially grow within tumor cores due to the immunoprivileged nature of the often hypoxic and necrotic tumor microenvironment [16] [17] [18] , and can locally affect tumor growth through the recruitment and activation of leukocytes. This selective colonization has provided an opportunity for using bacteria as drug delivery vehicles for the local expression of recombinant therapeutics in tumors 6 . With the advent of synthetic biology over the past two decades and the development of numerous bacteria gene circuits [19] [20] [21][22][23] , we reasoned that programming bacteria to controllably release recombinant immunotherapies could allow for local delivery of higher effective concentrations of therapy while preventing toxicities observed following systemic delivery of identical or similar therapeutic agents.
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To test the efficacy of this approach, we chose to target CD47, a potent anti-phagocytic receptor overexpressed in several human cancers 10, 11, 24 . Recent studies have shown that CD47 blockade not only increases phagocytosis of cancer cells but also promotes cross presentation of tumor antigens by dendritic cells to enhance priming of antitumor effector T cells in syngeneic murine tumor models [25] [26] [27] . However, as demonstrated in both preclinical models 11 and human trials 28, 29 , CD47 blockade using systemically delivered antibodies can result in anemia and thrombocytopenia due to high expression of CD47 on red blood cells and platelets respectively.
To improve upon its therapeutic profile, a nanobody (camelid single heavy chain antibody fragment) against CD47 with ~200-fold higher binding affinity than the commercially available antimouse CD47 monoclonal antibody (miap301) was recently developed and characterized 9 . This nanobody demonstrated mild effects as a systemically administered monotherapy, potentially due to lack of Fc-mediated effector functionwhen used in combination with a tumor specific antibody and systemic immune checkpoint blockade. In this work, we engineered an E. coli strain containing a synchronized lysis circuit (eSLC) that colonizes tumors and undergoes intratumoral quorum-lysis to locally release an encoded nanobody antagonist of CD47 (eSLC-CD47nb) (Fig. 1a) . This system allows for the combined local delivery of a novel immunotherapeutic along with immunostimulatory bacterial lysis adjuvants to stimulate antitumor immunity and promote tumor regression.
To confirm expression and lysis-dependent release of CD47nb, we first transformed nonpathogenic E. coli with a single plasmid encoding the synchronized lysis circuit (eSLC), as well as a stabilized plasmid driving constitutive expression of a hemagglutinin (HA)-tagged variant of CD47nb ( Supplementary Fig. 1 ). The SLC strain grows and produces the quorum-sensing molecule acylhomoserine lactone (AHL) via expression of luxI, then lyses at a critical threshold due to the production of a bacteriophage lysis protein (x174E), resulting in bacterial death and nanobody functionally binds CD47, A20 murine lymphoma cells, known to express CD47 25 , were incubated with a fixed concentration of FITC-labeled anti-mouse CD47 mAb (clone miap301) and varying dilutions of bacterial lysate from eSLC-CD47nb or eSLC expressing and empty vector ( Fig. 1c and Supplementary Fig. 2c ). We observed a progressive reduction in CD47 staining when cells were incubated with lysates from bacteria expressing CD47nb, suggesting that bacterially produced CD47nb could effectively outcompete miap301 binding to CD47 on the surface of A20 cells. Overall, these results indicate that SLC-CD47nb releases CD47nb in a lysisdependent manner and that CD47nb produced by engineered eSLC-CD47nb is capable of binding a similar CD47 epitope on tumor cells as the therapeutically effective miap301 mAb.
We next sought to evaluate the clinical efficacy for eSLC-CD47nb bacteria in a syngeneic mouse model. BALB/c mice were implanted with 5 x 10 6 A20 cells in both hind flanks. When tumors reached 100-150 mm 3 in volume, mice were randomly divided into three groups (PBS, eSLC, eSLC-CD47nb) and received intratumoral injections of PBS, or 10 7 colony forming units (CFU) of eSLC or eSLC-CD47nb bacteria resuspended in PBS, every 3-4 days for a total of 4 doses (Fig.   2a) . While administration of control eSLC alone initially slowed tumor growth, likely due to the activation of innate immune cells by bacterial products released upon quorum-lysis, final tumor volumes were not statistically different from PBS treated mice. In contrast, administration of eSLCCD47nb resulted in rapid and durable clearance of established A20 tumors within ~10 days of commencing therapy ( Fig. 2b and Supplementary Fig. 3a and 3b ). Significant therapeutic efficacy was also observed when eSLC-CD47nb was intratumorally injected in a syngeneic murine model of triple negative breast cancer (TNBC) (Supplementary Fig. 4a-d) . Of note, ~80% of mice treated with eSLC-CD47nb survived >90 days (Fig. 2c) and surviving mice were resistant to rechallenge upon subcutaneous injection of 10 x 10 6 A20 cells (data not shown), while naïve mice receiving the same batch of cells developed tumors within a week of injection. Furthermore, in contrast to animals receiving intratumoral injections of PBS or control eSLC bacteria, liver metastases were rarely observable in mice treated with eSLC-CD47nb when monitored at 30 days post-treatment (Fig. 2d) . Additionally, lung metastases were notably reduced in mice receiving eSLC-CD47nb in the 4T1 TNBC model ( Supplementary Fig. 4b-d) . We also assessed the biodistribution of eSLC-CD47nb bacteria 72 hours post treatment. Growth remained restricted to tumors (~2 x 10 8 CFU) and no bacteria could be cultured from the livers or spleens of treated mice above the limit of detection (~1 x 10 3 CFU) (Supplementary Fig. 5b ). Furthermore, bacterial therapy was well-tolerated by animals with no changes in body weight observed over the course of treatment or throughout the observation period (Supplementary Fig. 3b) . Overall Fig. 6b ). Moreover, immunophenotyping of A20 tumors treated with eSLC-CD47nb revealed increased proliferation of both Foxp3 -CD4 + and CD8 + T cells ( Fig. 3a and 3b ) in comparison to tumor bearing mice treated with eSLC bacteria. Furthermore, tumor-infiltrating Foxp3 -CD4 + T cells from eSLC-CD47nb-treated tumors produced significantly higher levels of IFN- following ex vivo restimulation with PMA and ionomycin ( Fig. 3b and 3c) . While eSLC-CD47nb did not lead to significant changes in IFN- levels in CD8 + T cells (Supplementary Fig. 7f ), we observed markedly elevated levels of intratumoral Granzyme B + CD8 + T cells (Fig. 3d) . Additionally, these T cell responses appeared to be tumor antigen-specific as overnight in vitro co-culture of irradiated A20 cells with splenocytes derived from mice treated with eSLC-CD47nb led to robust secretion of IFN- (Supplementary Fig. 8 ). Interestingly, mice treated with miap301 exhibited no elevated IFN- response in comparison to those receiving eSLC-CD47nb. These data suggest that eSLC-CD47nb not only support the activation ( Supplementary Fig. 7a and 7b ) and tumors on both flanks were treated with eSLC-CD47nb in a unilateral fashion (Fig. 4a) . While control eSLC bacteria had no effect on the growth of untreated tumors, treatment of the primary tumor with eSLC-CD47nb substantially slowed the growth of untreated tumors on the opposing flank ( Fig. 4b and 4c, Supplementary Fig. 5a ). To further quantify this effect, we computed the mean growth rates (mm/day) of treated vs. untreated tumors by calculating the slopes in tumor volume trajectories for each mouse (Fig. 4c) . These data indicated that eSLC-CD47nb treated mice showed decreased growth rates in both treated and untreated tumors compared to controls.
We considered the possibly that SLC-CD47nb bacteria injected into the primary tumor migrated via systemic circulation to seed the untreated lesion; however, both at 72 hours and 30 days post- 
METHODS

Strains and Plasmids
Plasmids were constructed using Gibson assembly or standard restriction enzyme-mediated cloning methods. The pSC01 SLC plasmid was constructed by first amplifying a region containing the constitutively expressed luxR gene and phage lysis gene, x174E under the control of luxI promoter from a pZA35E plasmid 7 . Next, this was cloned into a pTD103-luxI plasmid 22 using the AvrII site. The pSC02 therapeutic plasmid was constructed by cloning a gBlock (IDT) encoding a tac promoter and an E. coli codon-optimized sequence for the A4 anti-CD47 nanobody 9 with an C-terminal hemagglutinin tag into the multiple cloning site of a pAH162 plasmid 32 . Additionally, two stabilizing elements, the hok/sok system 33 and alp7 partitioning system 34 were introduced into pSC02 to minimize plasmid loss in vivo. pSC01 and pSC02 were transformed into chemically competent E. coli Pir1 + (Invitrogen). eSLC strains were grown in LB media with 50 µg/mL kanamycin (pSC01) and 100 µg/mL tetracycline (pSC02) along with 0.2% glucose at 37°C for under 12 hours in a shaking incubator. Glucose was added to reduce expression from the Lux promoter and prevent lysis in vitro.
Synchronized Lysis Circuit (SLC) characterization
To validate SLC function, +SLC and -SLC E. coli were inoculated into LB media containing appropriate antibiotics and diluted 1:10. Samples were grown at 37°C in a round bottom 96 well plate in a shaking Tecan plate reader. OD600 was recorded every 10 minutes for 20 hours. Agar pads were prepared according to previous protocols 31 . +SLC and -SLC E. coli were inoculated into LB media containing appropriate antibiotics and grown to mid-log phase. They were diluted 1:100 and grown under agar pads at 37°C and imaged using a Nikon Ti-E microscope equipped with an Okolab stage top incubator.
Bacterial nanobody characterization
Overnight cultures of E. coli containing pSC01 and pSC02 were grown in appropriate antibiotics and 0.2% glucose. A 1:100 dilution into LB with antibiotics was made the following day and bacteria were grown in a shaking incubator at 37°C. Optical Density (OD) was measured every 30 mins until the OD of lysing strains began to fall, indicating lysis. At this point OD normalized bacteria were spun down at 3000 rcf and supernatants were filtered through a 0.2 µm filter. Cell 
Flow cytometry
Tumors were extracted for immunophenotyping on day 8 following commencement of bacterial therapy. Lymphocytes were isolated from tumor tissue by mechanical homogenization of tumor tissue followed and digestion with collagenase A (1 mg/ml; Roche) and DNase I (0.5 µg/ml; Roche) in isolation buffer (RPMI 1640 supplemented with 5% FBS, 1% l-glutamine, 1% pen-strep and 10 mM Hepes) for 1 hour at 37°C. Cells were filtered through 100 µm cell strainers, washed in isolation buffer and stained. Dead cells were excluded by staining with Ghost Dye cell viability reagent. Extracellular antibodies used included anti-B220 (BD), anti-CD4 (Tonbo), anti-CD8
(eBioscience) and anti-NKp46 (BD). To measure T cell production of cytokines, cells were stimulated for 2 hours with PMA (50 ng/ml Sigma), ionomycin (1nM; Calbiochem) in the presence of GolgiPlug (brefeldin A). Following extracellular staining with the aforementioned antibodies, intracellular staining was performed using anti-CD3 (Tonbo) anti-TCR (BD), anti-CTLA4
(eBioscience), anti-Foxp3 (eBioscience), anti-Ki-67 (Thermo), and cytokines (anti-IL-17
(eBioscience), anti-TNF- (eBioscience), anti-IFN- (Tonbo). Cells were fixed using Foxp3/transcription factor staining buffer set (Tonbo) as per manufacturer's protocol. Samples were analyzed using a BD LSRFortessa cell analyzer.
Statistical analysis
Statistical tests were calculated in GraphPad Prism 7.0 (Student's t-test and ANOVA). 
Data availability
The data that support the findings of this study are available within the paper and its supplementary information files. Additional data are available from the authors upon reasonable request. 
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